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AtherosclerosisAbstract Background: Patients with systemic lupus erythematosus (SLE) and antiphospholipid
syndrome (APS) are at increased risk of atherosclerosis, and occurs much earlier compared to
the general population even after accounting for traditional risk factors.
Aim of the work: To examine the association between serum TWEAK, leptin and subclinical
atherosclerosis in SLE and APS patients.
Patients and methods: Serum tumor necrosis factor (TNF)-like weak inducer of apoptosis
(TWEAK) and leptin were measured in 30 SLE patients, 26 SLE patients with secondary APS
(SLE–APS), 14 with primary APS (pAPS) and 20 age and sex matched control. The SLE disease
activity index (SLEDAI) was assessed in SLE patients. The intima media thickness (IMT) was mea-
sured by carotid ultrasound.
Results: Serum TWEAK was significantly higher in patients with pAPS (945.1 ± 16.2 pg/ml)
than in SLE–APS (755.3 ± 59.9 pg/ml), SLE patients (499.2 ± 47.1 pg/ml) and control
(129.6 ± 18.6 pg/ml) (p< 0.001). Also, serum leptin was significantly higher in pAPS
patients (14.0 ± 2.8 ng/ml) compared to that in SLE–APS (6.5 ± 0.9 ng/ml), SLE patientsof accel-
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j.ejr.2016.07.001(3.8 ± 1.2 ng/ml) and control (1.6 ± 0.6 ng/ml) (p< 0.001). The IMT was significantly increased
in the pAPS patients compared to SLE–APS group (p< 0.001), SLE patients (p= 0.006) and to
the control (p< 0.001). A significant correlation was found between TWEAK with the body mass
index and high density lipoprotein in SLE–APS and inversely with the random blood sugar and the
diastolic blood pressure in SLE patients. Serum leptin only significantly correlated with the total
leucocytic count in SLE patients.
Conclusion: Patients with pAPS are more liable to develop premature atherosclerosis even in the
absence of the traditional risk factors.
 2016 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a common autoim-
mune disease occurring predominantly in women during
reproductive age, it can present with a diversity of presenta-
tions with accumulation of manifestations over time. Manifes-
tations range from mild disease (e.g., arthralgia and skin
affection) to severe life-threatening disease (e.g., renal impair-
ment, severe cytopenias, cardiac involvement, or increased rate
of thromboembolic events) [1]. Antiphospholipid syndrome
(APS) is a prothrombotic autoimmune disease associated with
arterial and venous thrombosis, thrombocytopenia and preg-
nancy morbidity (fetal loss, pre-eclampsia, and eclampsia).
APS can occur as an isolated primary condition (pAPS) or
be associated with a connective tissue disorder such as SLE [2].
Accelerated atherosclerosis is more common and occurs
much earlier in women with SLE compared to the general pop-
ulation and it causes significant morbidity and mortality [3].
Traditional risk factors such as altered lipid levels, age, smok-
ing, hypertension and diabetes mellitus do not fully explain the
increased risk of cardiovascular disease, strongly suggesting
that autoimmunity contributes to accelerated atherosclerosis.
Early diagnosis of subclinical atherosclerosis can be estab-
lished using noninvasive imaging techniques as carotid Dop-
pler measuring carotid intima media thickness (IMT) and
novel biomarkers, which enables us to assess atherosclerotic
lesions at different stages of their development [4]. In Egyptian
SLE patients, insulin sensitivity and IMT were altered espe-
cially in those with metabolic syndrome (MetS) comorbidity
with an associated increase in disease activity and damage
[5]. The increased IMT was significantly associated with obe-
sity in SLE patients [6].
The likelihood that a single biomarker would be adequate
for predicting the risk of accelerated atherosclerosis in all
SLE patients is slim. It is hypothesized that a combination
of traditional risk factors and biomarkers as pro-
inflammatory high-density lipoprotein (piHDL), tumor necro-
sis factor (TNF)-like weak inducer of apoptosis (TWEAK),
leptin and homocysteine would be better predictors for sub-
clinical atherosclerosis [7].
TWEAK is a proinflammatory cytokine of the TNF super-
family. Through activation of the fibroblast growth factor-
inducible 14 (Fn14) receptor, TWEAK regulates cell prolifera-
tion, cell death and inflammation [8]. The available lines of evi-
dence have indicated that TWEAK might be a target for
therapeutic intervention in renal, vascular injury and neuropa-
thy. Since renal, vascular and neuropsychiatric complications
are frequently encountered in SLE, TWEAK-Fn14 pathwayet al. Serum tumor necrosis factor (TN
c lupus erythematosus and antiphosphomay be implicated in the pathogenesis of SLE [9]. In a study
on Egyptian SLE patients, urinary levels of TWEAK were sig-
nificantly associated with lupus nephritis [10].
The adipokine leptin functions as a hypothalamic modula-
tor of food intake, body weight and fat stores [11]. High circu-
lating leptin levels are seen in overweight individuals.
Hyperleptinemia in the general population is also associated
with atherosclerosis, hypertension and MetS [12]. In another
study on Egyptian SLE patients, serum leptin was significantly
elevated in those with CVD and dyslipidemia [13]. Conversely,
adiponectin is the most abundant human plasma adipocy-
tokine, and levels are reduced in type II diabetes and cardio-
vascular disease. In addition to the established role of
adipokines in energy homeostasis, leptin and adiponectin also
have immunomodulatory roles. The dual roles of adipokines in
the regulation of metabolism and the immune system have led
some investigators to postulate that leptin and adipokines may
provide a link between immune responses and atherosclerosis
[12].
The aim of our study is to study the role of soluble
TWEAK and serum leptin in the development of subclinical
atherosclerosis in SLE patients and those with APS and to
study the correlation of IMT with the serum level of soluble
TWEAK and leptin.
2. Patients and methods
This study was carried out to evaluate premature atherosclero-
sis in patients with SLE and measure the IMT within the car-
otid vessels using B-mode gray-scale, color, and spectral
Doppler techniques. Thirty patients fulfilling the Systemic
Lupus International Collaborating Clinics (SLICC) classifica-
tion criteria for SLE [14], 26 patients with APS secondary to
SLE, 14 patients with primary APS and 20 (age and sex
matched) normal control subjects were recruited for this study.
Patients were recruited from the Internal Medicine and
Rheumatology outpatient clinic. The study was approved
department by the local university ethics committee and was
in accordance with the ethical standards of the 1964 Helsinki
declaration. All patients gave their informed consent prior to
their inclusion in the study. Patients with renal impairment
(serum creatinine >2 mg/dl), hypertension, diabetes and those
on statin therapy within the last 3 months were excluded from
the study as statins [15] and renal failure [16] are known to
alter HDL inflammatory function.
All the patients and control subjects were subjected to com-
plete medical history, clinical examination, body mass index
(BMI) measurement and SLE disease activity index (SLEDAI)F)-like weak inducer of apoptosis (TWEAK) and leptin as biomarkers of accel-
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tigations were done including complete blood count (CBC),
erythrocyte sedimentation rate (ESR), CRP, serum urea, crea-
tinine, alanine transaminase (ALT), aspartate transaminase
(AST), triglycerides, total cholesterol, high and low density
lipoproteins (HDL and LDL respectively), complement (C3
and C4), anti-nuclear antibody (ANA), anti-double stranded
deoxyribonucleic acid (anti-dsDNA), lupus anticoagulant
and anticardiolipin antibodies. Serum soluble TWEAK and
leptin were measured using ELISA technique.
2.1. Carotid ultrasound
B-mode gray-scale, color, and spectral Doppler techniques
were used to investigate the carotid arteries. All ultrasounds
were performed by 4 registered vascular technologists, who
were trained to perform the studies according to a preset pro-
tocol [18]. The same radiologist (NR) interpreted all studies,
and was blinded with regard to the patients’ demographic
characteristics, SLE status, and any previous ultrasound
results. The same ultrasound unit (Iu22; Philips Medical Sys-
tems) was used to scan all subjects. The following anatomic
sites were examined for the presence of atherosclerotic plaque,
defined as the presence of focal protrusion into the arterial
lumen with a thickness exceeding that of the surrounding wall
of at least 50%: the bilateral common carotid, internal carotid,
external carotid, and carotid bulbs. The number, location, and
sonographic appearance of the plaques were recorded. IMT of
the far wall of the distal common carotid artery was measured
1 cm proximal to the flow divider and at end diastole, using
automated QLab software (Philips Medical Systems). IMT
was never measured at the level of a plaque, and results are
presented as the mean of 3 values in the left and right seg-
ments. This definition of plaque has been found to be an inde-
pendent predictor of coronary heart disease events in the
general population [19].
Statistical analysis of data was done by IBM computer
using SPSS (statistical program for social science version 12)
as follows:
Mean SD and range: used for description of quantitative
variables.
Number and percentage: used for description of qualitative
variables.
Chi-square test: used to compare qualitative variables
between groups.
Spearman correlation test: used to rank different variables
against each others positively or inversely.
Unpaired t-test was used to compare quantitative variables,
in parametric data (SD< 50% mean).
One Way ANOVA test was used in case of comparison of
more than two groups as regard quantitative variables.
Mann Whitney test was used instead of unpaired t-test in
non parametric data (SD > 50% mean).
3. Results
Our study was conducted on 90 persons who were divided into
the following four groups: Group A included 30 SLE patients,
Group B included 26 patients with APS secondary to SLEPlease cite this article in press as: Badawi AIZ et al. Serum tumor necrosis factor (TN
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j.ejr.2016.07.001(SLE–APS), Group C included 14 patients with pAPS and
Group D (control group) included 20 healthy volunteers with
matched age and sex. Demographic features, laboratory inves-
tigations, serum TWEAK, serum leptin, SLEDAI and IMT of
the studied groups are illustrated in Table 1. The disease dura-
tion and BMI were significantly different in the SLE–APS
patients compared to the SLE (p= 0.019 and p= 0.005
respectively) and pAPS (p= 0.003 and p= 0.002 respec-
tively). The hemoglobin was significantly reduced in the SLE
patients compared to other groups (p< 0.01). The cholesterol
and triglycerides were significantly increased and the HDL
decreased in the SLE and pAPS patients compared to the con-
trol (p< 0.01). The HDL was significantly reduced in the SLE
compared to the SLE–APS patients. The serum cholesterol
and triglycerides were significantly increased in SLE–APS
compared to pAPS patients (p< 0.001). The ESR was signif-
icantly elevated in the patients compared to the control
(p< 0.01). Serum uric acid was significantly increased in the
SLE and pAPS patients compared to the control
(p< 0.001). The 24 h urinary protein was significantly
increased in the SLE and SLE–APS compared to the pAPS
patients (p< 0.001). Serum TWEAK and leptin were signifi-
cantly increased in the pAPS patients compared to the other
patients and control (p< 0.001). The IMT was significantly
increased in the pAPS patients compared to the SLE patients
(p= 0.006), SLE–APS (p< 0.001) and to the control
(p< 0.001). The SLEDAI was comparable between the SLE
and SLE–APS patients (p= 0.9). The levels of serum
TWEAK and leptin in the studied groups are demonstrated
in Figs. 1 and 2 respectively. The clinical manifestations of
the patients are shown in Table 2.
The correlations of sTWEAK and leptin with other param-
eters in SLE, SLE–APS and pAPS patients are shown in
Tables 3 and 4. A significant inverse correlation was found
between sTWEAK with RBS and with DBP in SLE patients.
There was no significant correlation with the lipid profile,
IMT or SLEDAI. Iin SLE–APS patients a significant correla-
tion was found between sTWEAK with the BMI and HDL.
No significant correlation was found with IMT or SLEDAI.
There’s no significant correlation of the sTWEAK and leptin
with lipid profile, IMT or SLEDAI in the pAPS patients.
4. Discussion
Systemic lupus erythematosus is associated with an increased
risk of subclinical and clinical atherosclerosis [20]. Traditional
risk factors such as altered lipid levels, older age, smoking,
hypertension and diabetes mellitus do not fully explain the
increased risk of cardiovascular disease, strongly suggesting
that autoimmunity contributes to accelerated atherosclerosis
[4]. Early diagnosis of subclinical atherosclerosis can be estab-
lished using noninvasive imaging techniques as carotid Dop-
pler measuring carotid IMT and novel biomarkers, which
enables us to assess atherosclerotic lesions at different stages
of their development, from endothelial dysfunction, through
morphological lesions in the arteries, to advanced atheroscle-
rotic plaques [7].
In our study, we found that serum TWEAK and leptin were
significantly higher in patients with pAPS than in SLE patients
with secondary APS. Serum levels were significantly higher in
patients with SLE–APS than in those with SLE only. SerumF)-like weak inducer of apoptosis (TWEAK) and leptin as biomarkers of accel-
ipid syndrome, The Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/
Table 1 Demographic features, laboratory investigations, disease activity and intima media thickness in the studied groups.
Variablemean ± SD SLE (n= 30) SLE–APS (n= 26) pAPS (n= 14) Control (n= 20) p
Demographic
Age (years) 26.1 ± 7.1 28.2 ± 5.1 28.7 ± 5.9 25.2 ± 4 0.15
Duration (months) 25.5 ± 22.9 43.7 ± 43.5 10.2 ± 9.7 - 0.007
BMI 26.9 ± 2.2 24.5 ± 3 26.8 ± 3.4 25 ± 1.9 0.004
SBP (mmHg) 115 ± 11.4 120.4 ± 10.8 116.4 ± 12.2 113 ± 12.2 0.18
DBP (mmHg) 73.3 ± 10.3 76.5 ± 4.9 73.6 ± 6.3 71.5 ± 10.4 0.28
Laboratory
Hb (g/dl) 9.3 ± 1.9 10.7 ± 1.3 10.8 ± 1.6 11.9 ± 0.7 <0.001
TLC (103/mm3) 6.7 ± 3 7.1 ± 3.4 8.7 ± 2.7 7.5 ± 1.8 0.09
PLT (103/mm3) 229.6 ± 129.1 273.2 ± 102.2 237.4 ± 120.1 268.8 ± 63.8 0.12
ESR (mm/1st h) 75 ± 37.6 65.1 ± 28.6 66.5 ± 35.5 16.5 ± 13.5 0.41
Chol (mg/dl) 188.9 ± 76.8 200.1 ± 69.7 170.3 ± 40 130.7 ± 16.2 <0.001
TG (mg/dl) 179.4 ± 115 152.8 ± 104.7 129.6 ± 32.8 87.8 ± 10.9 <0.001
HDL (mg/dl) 39.3 ± 14.9 52 ± 12.7 39.8 ± 10.8 49.7 ± 6.5 <0.001
LDL (mg/dl) 93.9 ± 65.8 98.9 ± 55.4 78.6 ± 30.3 80.6 ± 12.9 0.23
Urea (mg/dl) 45.3 ± 33.5 40.5 ± 28.1 30.4 ± 12.9 25.5 ± 3.8 0.04
Cr (mg/dl) 0.8 ± 0.3 0.9 ± 0.3 0.9 ± 0.2 0.9 ± 0.2 0.27
SUA (mg/dl) 6.4 ± 2.6 5.7 ± 1.1 6.1 ± 2.5 4.3 ± 0.6 <0.001
UP (g/24 h) 1.9 ± 2.7 1.1 ± 1.8 0.2 ± 0.1 – <0.001
C3 (mg/dl) 80.6 ± 54.9 75.3 ± 34.2 80.7 ± 23.4 – 0.68
C4 (mg/dl) 16.6 ± 15.1 15 ± 8.5 12.3 ± 4.7 – 0.70
Biomarkers
TWEAK (pg/ml) 499.2 ± 47.1 755.3 ± 59.9 945.1 ± 16.2 129.6 ± 18.6 <0.001
Leptin (ng/ml) 3.8 ± 1.2 6.5 ± 0.9 14 ± 2.8 1.6 ± 0.6 <0.001
SLEDAI 8.7 ± 3.3 9.4 ± 4.5 0.9
IMT (mm) 5.9 ± 1.6 5.8 ± 1.0 7.3 ± 0.7 5.8 ± 0.5 <0.001
SLE: systemic lupus erythematosus, SLE–APS: SLE with secondary antiphospholipid syndrome, pAPS: primary APS, BMI: body mass index,
SBP: systolic blood pressure, DBP: diastolic blood pressure, Hb: hemoglobin, TLC: total leukocytic count, PLT: platelets, ESR: erythrocyte
sedimentation rate, Chol: cholesterol, TG: triglycerides, HDL: high density lipoprotein, LDL: low density lipoprotein, Cr: Creatinine, SUA:
serum uric acid, UP: urinary protein, C: complement, TWEAK: tumor necrosis factor (TNF)-like weak inducer of apoptosis, SLEDAI: SLE
disease activity index, IMT: intima media thickness.
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Figure 1 Serum tumor necrosis factor (TNF)-like weak inducer
of apoptosis (TWEAK) in systemic lupus erythematosus (SLE)
patients with and without antiphospholipid syndrome (APS), in
primary APS patients and control.
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Figure 2 Serum leptin in systemic lupus erythematosus (SLE)
patients with and without antiphospholipid syndrome (APS), in
primary APS patients and control.
4 A.I.Z. Badawi et al.TWEAK and leptin were higher in patients compared to the
control. Similarly, a significant difference in sTWEAK and
leptin levels was found between SLE patients and controls.
Elevated leptin level contributes to increased oxidative stress
in endothelial cells [21] and cardiomyocytes [22] but further
studies are required to determine whether hyperleptinemia
contributes directly to increased oxidative stress in SLE.Please cite this article in press as: Badawi AIZ et al. Serum tumor necrosis factor (TN
erated atherosclerosis in patients with systemic lupus erythematosus and antiphospho
j.ejr.2016.07.001Leptin might promote atherosclerosis by several other mecha-
nisms; it increases the accumulation of cholesterol esters in
foam cells, especially in hyperglycemic conditions; it also acti-
vates circulating monocytes, induces monocyte proliferation
and upregulates endothelial cell production of monocyte
chemoattractant protein [23]. Our results are also in agreement
with ElGendi, et al., [24] who found that serum TWEAK wasF)-like weak inducer of apoptosis (TWEAK) and leptin as biomarkers of accel-
lipid syndrome, The Egyptian Rheumatologist (2016), http://dx.doi.org/10.1016/
Table 2 Clinical manifestations in the systemic lupus erthe-
matosus patients with and without antiphospholipid syndrome
(APS) and in the primary APS patients.
Clinical manifestation
n (%)
Patients (n= 70)
SLE
(n= 30)
SLE–APS
(n= 26)
pAPS
(n= 14)
Musculoskeletal 29 (96.7) 26 (100) 3 (21.4)
Oral ulcers 7 (23.3) 14 (53.8) –
Malar rash 19 (63.3) 15 (57.7) –
Photosensitivity 15 (50) 16 (61.5) –
Alopecia 15 (50) 17 (65.4) –
Nephritis 18 (60) 7 (26.9) –
Thrombosis 1 (3.3) 22 (84.6) 13 (92.9)
Recurrent abortions 0 (0) 11 (42.3) 6 (42.9)
Bleeding tendency 9 (30) 1 (3.8) 3 (21.4)
SLE: systemic lupus erythematosus, SLE–APS: SLE with sec-
ondary antiphospholipid syndrome, pAPS: primary APS.
TWEAK and leptin as biomarkers of accelerated atherosclerosis 5significantly higher in SLE patients compared to control group
especially those with lupus nephritis.
To our knowledge, this is the first study to link high serum
TWEAK levels to accelerated atherosclerosis in SLE and APS.
Soluble TWEAK is linked to increased rates of accelerated
atherosclerosis, inflammation, angiogenesis and apoptosis [7].
Administration of TWEAK to apolipoprotein E–deficient
mice resulted in a significant increase in plaque, which was
inhibited when mice were pretreated with anti-TWEAK anti-
bodies. One study showed that sTWEAK levels were signifi-
cantly elevated in patients with acute myocardial infarctionTable 3 Correlation between serum TWEAK level with various para
antiphospholipid syndrome (APS) and in the primary APS patients.
Variable r (p) Serum soluble TWEAK (pg/ml)
SLE (n= 30) S
Demographic
Age (years) 0.33 (0.08) 0
Duration (months) 0.08 (0.69) 
SBP (mmHg) 0.19 (0.33) 
DBP (mmHg) 0.47 (0.008) 
BMI 0.19 (0.31) 0
Laboratory
Hb (g/dl) 0.19 (0.31) 0
TLC (103/mm3) 0.002 (0.99) 0
PLT (103/mm3) 0.02 (0.93) 0
ESR (mm/1st h) 0.04 (0.83) 0
Chol (mg/dl) 0.07 (0.72) 0
TG (mg/dl) 0.17 (0.38) 0
HDL (mg/dl) 0.07 (0.72) 0
LDL (mg/dl) 0.04 (0.83) 0
C3 (mg/dl) 0.13 (0.49) 0
C4 (mg/dl) 0.03 (0.88) 0
SLEDAI 0.03 (0.89) 
IMT (mm) 0.15 (0.43) 0
TWEAK: tumor necrosis factor (TNF)-like weak inducer of apoptosis,
antiphospholipid syndrome, pAPS: primary APS, SBP: systolic blood p
hemoglobin, TLC: total leukocytic count, PLT: platelets, ESR: erythrocyt
density lipoprotein, LDL: low density lipoprotein, C: complement, SLED
Bold values are significant at p< 0.05.
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j.ejr.2016.07.001compared to patients with stable coronary disease and healthy
controls, and higher levels were associated with adverse short-
term post–myocardial infarction outcomes [25]. Another study
found that TWEAK can regulate expression and secretion of
High mobility group box 1 protein (HMGB1) in monocytes/-
macrophages, participating in the inflammatory response asso-
ciated with atherosclerotic plaque development [26] with
evidence suggesting a role for sTWEAK in the pathophysiol-
ogy of vascular calcification [27].
In the present study, no significant correlation between
serum TWEAK, leptin with the SLEDAI or IMT were found
nor was there a significant correlation between the IMT and
SLEDAI. These were consistent with Barbosa Vde, et al.,
[28] who found no significant difference in levels of leptin
between inactive and active SLE patients. The association of
sTWEAK with mortality was strongest in patients with inflam-
mation [29]. In disagreement are the results of McMahon,
et al., [7] who found a significant correlation between serum
leptin and SLE disease activity while high sTWEAK was asso-
ciated with mild to moderate SLE flares.
The IMT was significantly increased in pAPS patients com-
pared to SLE patients with or without secondary APS and
control. No significant differences were found between SLE
patients with or without secondary APS and control. The pos-
sible roles of antiphospholipid (aPL) in the pathogenesis of
thrombosis in APS include changes in the coagulation cascade,
inhibition of protein C, antithrombin and annexin, platelet
activation and complement, and increased expression of
endothelial adhesion molecules. However, other risk factors
and/or medical conditions can coexist in these patients raising
their risk of developing thrombosis [30].meters in systemic lupus erthematosus patients with and without
LE–APS (n= 26) pAPS (n= 14)
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0.01 (0.97) 0.07 (0.82)
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SLE: systemic lupus erythematosus, SLE–APS: SLE with secondary
ressure, DBP: diastolic blood pressure, BMI: body mass index, Hb:
e sedimentation rate, Chol: cholesterol, TG: triglycerides, HDL: high
AI: SLE disease activity index, IMT: intima media thickness.
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Table 4 Correlation between serum leptin level with various parameters in systemic lupus erthematosus patients with and without
antiphospholipid syndrome (APS) and in the primary APS patients.
Variable r (p) Serum leptin (ng/ml)
SLE (n= 30) SLE–APS (n= 26) pAPS (n= 14)
Demographic
Age (years) 0.02 (0.93) 0.16 (0.43) 0.09 (0.76)
Duration (months) 0.3 (0.11) 0.004 (0.98) 0.52 (0.06)
SBP (mmHg) 0.05 (0.79) 0.07 (0.75) 0.29 (0.32)
DBP (mmHg) 0.18 (0.35) 0.24 (0.24) 0.08 (0.78)
BMI 0.32 (0.09) 0.04 (0.86) 0.28 (0.33)
Laboratory
Hb (g/dl) 0.13 (0.5) 0.32 (0.12) 0.32 (0.37)
TLC (103/mm3) 0.46 (0.01) 0.08 (0.7) 0.19 (0.6)
PLT (103/mm3) 0.27 (0.16) 0.04 (0.84) 0.12 (0.74)
ESR (mm/1st h) 0.11 (0.58) 0.23 (0.25) 0.08 (0.8)
Chol (mg/dl) 0.02 (0.93) 0.03 (0.89) 0.2 (0.49)
TG (mg/dl) 0.17 (0.37) 0.03 (0.89) 0.11 (0.7)
HDL (mg/dl) 0.07 (0.73) 0.19 (0.36) 0.26 (0.36)
LDL (mg/dl) 0.09 (0.65) 0.15 (0.47) 0.01 (0.98)
C3 (mg/dl) 0.29 (0.13) 0.02 (0.94) 0.3 (0.29)
C4 (mg/dl) 0.1 (0.59) 0.25 (0.22) 0.02 (0.96)
SLEDAI 0.04 (0.84) 0.11 (0.61) – –
IMT (mm) 0.26 (0.16) 0.21 (0.31) 0.05 (0.87)
SLE: systemic lupus erythematosus, SLE–APS: SLE with secondary antiphospholipid syndrome, pAPS: primary APS, SBP: systolic blood
pressure, DBP: diastolic blood pressure, BMI: body mass index, Hb: hemoglobin, TLC: total leukocytic count, PLT: platelets, ESR: erythrocyte
sedimentation rate, Chol: cholesterol, TG: triglycerides, HDL: high density lipoprotein, LDL: low density lipoprotein, C: complement, SLE-
DAI: SLE disease activity index, IMT: intima media thickness.
Bold values are significant at p< 0.05.
6 A.I.Z. Badawi et al.In conclusion, patients with pAPS are more liable to
develop premature atherosclerosis even in the absence of the
traditional risk factors. Serum TWEAK and leptin were
remarkable increased in pAPS and SLE patients with and
without APS making them potential biomarkers in the patho-
genesis of both diseases. There was no relation of these two
biomarkers to the other risk factors or IMT however, in
SLE patients with APS, TWEAK significantly correlated with
the HDL. Future longitudinal studies on a larger number of
patients are encouraged, assessing the utility of adding or sub-
stituting alternate biomarkers into the atherosclerotic panel is
needed and identification of high-risk subjects can direct
prospective preventative treatment strategies.
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